AZD2014 + AZD8186

AZD2014 + AZD8186 is an investigational combination therapy comprising two small molecule inhibitors developed by AstraZeneca for the treatment of advanced solid tumors, particularly those with PTEN deficiency or PI3K pathway alterations. - **AZD2014 (vistusertib)** is a dual inhibitor of mTORC1 and mTORC2 complexes, targeting the mammalian target of rapamycin (mTOR) pathway to inhibit cancer cell growth and proliferation. - **AZD8186** is a potent and selective inhibitor of phosphatidylinositol 3-kinase beta (PI3Kβ) and delta (PI3Kδ), designed to block signaling in PTEN-deficient tumors that are dependent on deregulated PI3Kβ activity. The rationale for combining these agents is to achieve comprehensive inhibition of the PI3K/AKT/mTOR signaling axis, which may provide greater antitumor efficacy than either agent alone in cancers driven by this pathway. The combination has been evaluated in phase I clinical trials for safety, tolerability, pharmacodynamics, and preliminary efficacy in patients with advanced castrate-resistant prostate cancer (CRPC), triple-negative breast cancer (TNBC), squamous non-small cell lung cancer (sqNSCLC), and other solid malignancies with relevant molecular alterations[5][7].

Other names

vistusertib + AZD8186